Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Clinical trial NCT04175262 · COMPLETED
Trial details
- NCT number
- NCT04175262
- Sponsor
- Pfizer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2019-10-31
- Primary completion
- 2020-03-09
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.